NCT04525144View on ClinicalTrials.gov

EGb 761 in the Syndrome of MCI With Concomitant CVD

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

November 30, 2026

Conditions
Mild Cognitive ImpairmentCerebrovascular Disease
Interventions
DRUG

Tebonin Forte

Dietary supplement: Gingko biloba EGb 761

Trial Locations (1)

308433

RECRUITING

National Neuroscience Institute, Singapore

Sponsors
All Listed Sponsors
collaborator

Dr. Willmar Schwabe GmbH & Co. KG

INDUSTRY

lead

National Neuroscience Institute

OTHER